A combination of Moderna’s mRNA vaccine and Merck’s Keytruda immunotherapy drug significantly extended the time patients lived without melanoma returning in a late-stage clinical trial involving more than 1,100 higher-risk or advanced melanoma patients. Moderna’s stock price more than doubled on Wednesday following the reported results. The trial demonstrated that the combination regimen extended the period before melanoma returned compared to treatment with Keytruda alone.
The Washington Examiner reported the stock price increase, noting the successful results from the mRNA shot in the clinical trial. CNBC also highlighted the positive trial results and the subsequent surge in Moderna’s stock price. No right-leaning outlets beyond the Washington Examiner reported on the results.
The data suggests a potential advancement in melanoma treatment, though further research will be needed to confirm these findings and assess long-term efficacy and safety.
We don't rate truth. We strip the spin and show you which perspectives covered the story. You decide.
Read the original coverage
💬 Comments
📜 Comment Policy